PS PeptideSuppliers.org The peptide supplier database
Blog · October 25, 2026

Tesamorelin explained: what it is, how it is studied, and how to evaluate suppliers

Tesamorelin is one of the most studied growth hormone-releasing hormone (GHRH) analogs, and it is also one of the easiest peptides to misunderstand. It is a prescription drug in one form and a laboratory research chemical in another. This guide explains what the compound is, how it is studied, what separates a well-documented research batch from a poorly documented one, and how to evaluate suppliers that list it.

Everything on PeptideSuppliers.org is about laboratory research materials. This article does not give dosing, administration, or medical advice, and nothing here is intended for human or veterinary use. See our medical disclaimer.

What tesamorelin is

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone, the 44-amino-acid hypothalamic peptide that signals the pituitary gland to release growth hormone. Its sequence follows the full length of human GHRH(1–44), with one deliberate change: a trans-3-hexenoyl group is attached to the N-terminus of the peptide. Its molecular weight is roughly 5.1 kDa, which makes it a much larger molecule than short research peptides such as BPC-157 (15 amino acids) or KPV (3 amino acids).

That size matters for anyone sourcing it. Longer peptides are harder to synthesize and purify, they are more prone to truncated or modified by-products, and their analytical profile is more complicated. A purity figure that looks excellent for a 15-residue peptide can mean something different for a 44-residue one, which is why the documentation questions later in this article are especially important for tesamorelin.

Why the N-terminal modification exists

Natural GHRH is cleared from the body very quickly. A major reason is an enzyme called dipeptidyl peptidase-4 (DPP-4), which cleaves two amino acids from the N-terminus and inactivates the hormone within minutes. The trans-3-hexenoyl group on tesamorelin was introduced to make the molecule more resistant to that cleavage, so that the intact peptide persists long enough to be studied and used as a reference compound.

This is the main reason tesamorelin is described as a “stabilized” GHRH analog. The core sequence is still the one the GHRH receptor recognizes; the change is at the end that DPP-4 attacks. It also explains why tesamorelin is often compared with CJC-1295 without DAC, a shorter GHRH analog (a modified 29-amino-acid fragment) that is built differently and behaves differently in assays.

How it is studied in the laboratory

Tesamorelin acts at the GHRH receptor on pituitary somatotroph cells. In research settings the receptor engagement leads to cyclic AMP signaling and the release of growth hormone, which in turn drives downstream insulin-like growth factor 1 (IGF-1) production in the liver and other tissues. Because tesamorelin acts upstream of growth hormone and not by supplying growth hormone itself, it is used to study how the GH axis responds to receptor stimulation, including the pulsatile pattern of GH release.

Typical research questions include:

  • Receptor pharmacology: binding, signaling, and desensitization at the GHRH receptor in cell-based assays.
  • Pituitary models: how somatotroph cells or pituitary tissue respond to GHRH analogs compared with other secretagogues.
  • GH/IGF-1 axis biology: how stimulation upstream changes IGF-1 and related markers in experimental systems.
  • Metabolic and lipid-marker work: how GH-axis signaling relates to fat metabolism and lipid markers in published models.
  • Comparative studies: head-to-head work with other GHRH analogs and with ghrelin-receptor agonists such as ipamorelin.

Reference compounds are valuable only when their identity and quality are known. A receptor study run with an under-dosed, degraded, or mislabeled batch can produce results that look like biology but are really chemistry. That is the argument for treating documentation as seriously as price.

Regulatory context: a drug and a research chemical

Tesamorelin is also an approved medicine. In 2010 the US Food and Drug Administration approved a tesamorelin product for a specific clinical indication in adults with HIV-associated lipodystrophy. We mention this for context, not as guidance: it is the reason tesamorelin has an unusually deep body of published clinical literature compared with most peptides in our database.

It is also the source of confusion. The approved medicine is a manufactured, regulated, prescription product with defined manufacturing standards. The tesamorelin sold by research suppliers is a different thing: a laboratory material sold for research use only, with whatever quality its manufacturer and tester can document. The two should not be treated as interchangeable, and research suppliers state that their materials are not for human or veterinary use. Laws on buying, possessing, and importing these materials differ by country, so check the rules where you are before ordering.

What a good tesamorelin batch record should show

Because tesamorelin is a large peptide, the questions below matter more than they do for short peptides. Our introduction to the site describes our general approach; here is how it applies to this compound.

  1. Identity by mass spectrometry. HPLC retention time alone does not prove the molecule is tesamorelin. A mass-spec result confirming the expected molecular weight (about 5.1 kDa) is the stronger identity check. Ask which method the report used.
  2. Purity by HPLC, with the method stated. A purity percentage is only as meaningful as the method behind it. Look for the wavelength, the gradient or column details if provided, and the date. For a 44-residue peptide, a figure in the high 90s is common, but the report should show the chromatogram or at least name the method.
  3. Content versus label. A vial labeled 10 mg may not contain 10 mg of peptide. Lyophilized peptides include counterions and residual water, so measured content can differ from the nominal amount. A report that states the measured quantity against the label is more informative than one that only gives purity.
  4. Endotoxin and sterility, if claimed. If a supplier says the material is tested for endotoxin or sterility, the report should say so, with the method and the specification. Not every report includes every assay, and purity does not prove sterility.
  5. Lot linkage. The report should name a batch or lot number that matches the vial you receive, plus the laboratory, the date, and ideally a way to verify it with the lab itself. A single report for a different lot is evidence about that lot only.

A report that covers these points is not a guarantee, because it describes the sample tested. But it is far better than a general “third-party tested” badge, and it makes mistakes and inconsistencies easier to spot.

Handling notes from the research literature

Suppliers and researchers describe a few practical issues with tesamorelin in the laboratory. These are general handling points, not usage instructions:

  • Storage of lyophilized material. Most suppliers specify cold, dark, dry storage of the sealed lyophilized powder and warn against repeated freeze–thaw cycles once the material is in solution. Follow the storage conditions printed on the certificate and the label.
  • Solubility and gelling. Because it is a long peptide, tesamorelin can be slow to dissolve and may form gels or clumps under some conditions. At least one supplier publishes a technical note on tesamorelin gelling, which tells you the issue is common enough to document. Check solubility data for your own protocol before planning work.
  • Counterion and salt form. The salt form (often an acetate) affects the mass-to-peptide ratio and solubility. If a report does not say how content was measured, ask.
  • Documentation after opening. Record the lot number, date, and storage history of every vial. Stock that cannot be traced to a certificate is hard to troubleshoot when results look odd.

Comparing tesamorelin with related compounds

Researchers often compare tesamorelin with other GH-axis tools. A short orientation:

  • CJC-1295 (no DAC): a shorter GHRH analog with several amino-acid substitutions. It acts at the same receptor, but it is a different molecule with different stability and analytical behavior.
  • Ipamorelin: a growth hormone secretagogue that acts at the ghrelin receptor (GHS-R), a different pathway from GHRH analogs. It is frequently studied alongside GHRH analogs, and blends of CJC-1295 and ipamorelin are common in supplier catalogs.
  • Sermorelin: a shorter GHRH fragment (the first 29 residues) that is the older, simpler relative of these analogs.

Choosing among them is a question of the experimental design, not of which is “stronger.” We bring them up because suppliers sometimes group them together on a single page, and their documentation needs are not identical. A report for a blend should show how each component was measured.

Using the database to find a tesamorelin supplier

If you are looking for tesamorelin, the quickest route is the supplier database filtered to tesamorelin. From there you can narrow by published COA status, price tier, country, and shipping. Each result links to a full review so you can see what we could and could not verify.

As an illustration of why the documentation filter matters, here is how three suppliers in the database present tesamorelin as of late October 2026. Prices are for a 10 mg vial and change often:

  • Aurelia Research lists tesamorelin with a batch-level certificate (purity reported at 99.60% for the batch in its library) and a lookup page that names the laboratory and test date. It is a new company, so we note its short history. US listing was about $84.99.
  • Disguised Alpha lists tesamorelin in 5, 10, and 20 mg sizes (10 mg about $79.99) and has a large COA portal, though we flag that its testing and payment claims differ between pages.
  • Ageless Peptides lists tesamorelin 10 mg at about $89.99 with bundle pricing, but we found no visible lab report on that product page.

Prices alone would rank these differently than documentation does. That is the point: with a 44-residue peptide, a low price with no batch record is a bigger gamble than a modest premium with a verifiable report. We rate documentation and buyer risk, not product quality, because we do not run our own assays, and we say on each review whether we have ordered.

A short checklist before you order tesamorelin

  1. Confirm the exact material, strength, and salt form you need.
  2. Find a batch-specific report that names the lab, the method, and the lot, and verify it with the lab if a link is offered.
  3. Check that identity was confirmed by mass spectrometry, and that content is reported against the label.
  4. Compare delivered price, including shipping, bundles, and any minimum order.
  5. Look at payment options and the refund policy before you fill the basket. Card payments allow disputes; bank transfers, crypto, and peer-to-peer apps usually do not.
  6. Check the laws that apply to you for purchase, possession, and import.

The bottom line

Tesamorelin is a well-characterized GHRH analog with a long research history, a modified 44-residue structure, and an unusual dual identity as both a regulated medicine and a research chemical. For a laboratory buyer, the right questions are about identity, purity, content, and traceability, not marketing language. Use the database filter, read the batch record, and keep your own records. If a supplier is missing, a detail is out of date, or you have a documented experience to share, tell us.